Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Video game therapy could replace eye patches for lazy eye

NCT ID NCT07323953

Disease control Sponsor: Eyesight Electronics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new digital therapy called AmblyoFix for treating lazy eye (amblyopia) in children aged 7 to 12. The therapy uses special software and red-blue glasses to play visual games that stimulate the weaker eye. Researchers will compare results to a group of children who previously received standard eye patching, to see if AmblyoFix is as effective and easier for kids to use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AmblyoFix binocular digital therapy (software and red-blue glasses)
What this could lead to
If successful, AmblyoFix could offer a more engaging and easier-to-stick-with alternative to eye patching for treating lazy eye in children.
What could go wrong
This is a small, early-stage trial with only 33 participants, and it compares against past patients rather than a simultaneous control group. The therapy may not work as well as patching for all children.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 33 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

7 to 12 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 7-12 years. * Unilateral amblyopia secondary to anisometropia and/or mild strabismus. * BCVA in amblyopic eye between 20/40-20/400 (0.3-1.3 logMAR); fellow eye ≥20/32 (≤0.2 logMAR). * Interocular difference ≥2 lines (≥0.2 logMAR). * Stable refractive correction for ≥16 weeks or \<0.1 logMAR change across two visits ≥8 weeks apart. * Cycloplegic refraction within 7 months meeting anisometropia criteria (e.g., hyperopia ≥+2.50 D). * Access to a suitable home environment (laptop and internet). * Parent/guardian consent and child assent (7+ year olds). Exclusion Criteria: * Atropine use within 2 weeks before starting treatment * Prior amblyopia treatment beyond refractive adaptation. * Myopia \>-6.00 D SE, previous ocular surgery, or other ocular pathology. * Severe cognitive/developmental delay impeding compliance. * History of light-induced seizures. * Inability/unwillingness to comply with digital monitoring. * Any condition compromising safety or trial integrity.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Amblyopia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

amblyopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Amblyopia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Watany Research and Development Center, Watany Eye Hospital

    RECRUITING

    Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.